503b bulk list exclusion
30% Cost Rise Hits Clinics After FDA Cuts Semaglutide Supply
The FDA’s new rule will increase clinic drug costs by about 30 percent. By removing semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list, manufacturers must shift to higher-priced licensed pharmacies, pushing up wholesale prices and patient bills. Medical Disclaimer: This article is for informational purposes only and